Boston University is the home of CARB-X and at the heart of its operations. CARB-X is not a separate legal entity, but is fully a part of the University’s non-profit research mission. CARB-X is funded by the US Biomedical Advanced Research and Development Authority (BARDA),  the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF), the Bill & Melinda Gates Foundation, with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID).

Boston University is a major global research university and a member of the American Association of Universities, with more than 10,000 faculty working with 33,000 students from around the world. Total funded research at BU in FY 2018 exceeded $486 million.